We have shown that IL-1␤ is not detectable in normal plasma cells but is produced by plasma cells from virtually all patients with multiple myeloma (MM). To extend our earlier work, IL-1␤ expression was determined in 13 newly diagnosed patients with IgM monoclonal gammopathy. Eleven patients with Waldenstrom's macroglobulinemia (WM) and two patients with IgM MM were investigated for IL-1␤ expression by in situ hybridization (ISH). All patients with WM had bone marrow biopsies consistent with the diagnosis, an IgM M-protein in the serum, and subsequently required chemotherapy. Seven of 11 patients with WM had an M-protein Ͼ3 g/dl and five patients had bone surveys performed that were negative for osteolytic disease. Two patients were diagnosed with IgM MM because of the presence of significant osteolytic disease on a metastatic bone survey. ISH for kappa, lambda, and IL-1␤ expression was performed on bone marrow aspirates from each of the 13 patients. None of the neoplastic cells from the 11 patients with WM showed detectable IL-1␤ expression by ISH. However, the neoplastic cells from both patients with IgM MM expressed IL-1␤ mRNA at high levels. This aberrant IL-1␤ production may explain the presence of bone lesions in the patients with IgM MM. Leukemia (2002) 16, 382-385.
Introduction
We have previously shown that IL-1␤, which is undetectable in normal plasma cells, is abnormally expressed in virtually all myeloma patients and approximately 25% of patients with monoclonal gammopathy of undetermined significance (MGUS). [1] [2] [3] IL-1␤ has potent osteoclast activating factor (OAF) activity, can induce the expression of several adhesion molecules such as ICAM-1 and VCAM-1 and stimulate interleukin-6, the central growth factor for myeloma cells. [4] [5] [6] [7] [8] [9] These biologic effects of IL-1␤ closely parallel several of the clinical features of human myeloma suggesting that upregulation of IL-1␤ may be critical to the pathogenesis of the disease. 3, 10 To extend our earlier work, we have now investigated the role of IL-1␤ expression in 11 patients with Waldenstrom's macroglobulinemia (WM) and two patients with IgM multiple myeloma (MM). Clinically, Waldenstrom's macroglobulinemia differs from MM in many respects. For example, bone lesions are common at presentation in patients with MM and are detectable in virtually all individuals in the terminal phase of the disease. 10, 11 In contrast, osteolytic disease is present in less than 10% of patients with WM. [12] [13] [14] We hypothesized that differences in IL-1␤ production may account for some of the clinical differences between MM and WM. 
Materials and methods

Patients
Bone marrow aspirates were obtained from 13 newly diagnosed patients -11 patients with Waldenstrom's macroglobulinemia and two patients with IgM multiple myeloma. Diagnoses were established using previously published criteria. 15 All samples used in this study were obtained from patients with written informed consent according to Institutional Review Board Guidelines.
In situ hybridization for IL-1␤
In situ hybridization (ISH) for IL-1␤ expression was performed as previously described.
1,2 Briefly, paraformaldehyde fixed cells from Ficoll-Hypaque density gradient purified bone marrow aspirates were hybridized with a digoxigenin-11-dUTP labeled (Boehringer-Mannheim, Indianapolis, IN, USA) antisense oligonucleotide probe specific for the human IL-1␤ gene (5′-ACACAAATTGCATGGTGAAGTCAGTT-3′). For each patient, a positive and negative control was run using commercially available FITC-labeled kappa and lambda probes (DAKO Corp, Carpinteria, CA, USA). A blank slide without probe was run on each patient to control for nonspecific staining. An anti-probe antibody was added (anti-digoxigenin-AP for the IL-1␤ and blanks; anti-FITC-AP for the kappa and lambda). The reactions were developed in NBT/BCIP. Hematoxylin was used as a nuclear counterstain. Slides were examined microscopically and plasma cells were scored as positive or negative for IL-1␤ mRNA. A patient was considered to be positive for IL-1␤ expression by ISH if у50% of the neoplastic cells were IL-1␤ positive. Each slide was scored independently by two different readers (KAD, JAL).
Flow cytometry and reverse transcriptase/polymerase chain reaction (RT/PCR) for IL-1␤ Expression
Flow cytometry and RT/PCR were performed as previously described. 1 Briefly, 25-30 million mononuclear cells from bone marrow aspirates were stained with a fluorescein (FITC)-conjugated monoclonal antibody to CD45 and a phycoerythrin (PE)-conjugated antibody against CD38 (Becton Dickinson, San Jose, CA, USA). Myeloma cells are typically CD38 positive/CD45 negative or intermediate. Using a FACStar Plus flow cytometer, debris and nucleated red blood cells were excluded by gating on the larger cells as defined by intermediate-to-high forward and negative-to-intermediate orthogonal light scatter. The CD38 + /CD45 − region was collected and contained greater than 95% plasma cells for all patients. This was confirmed morphologically. 1 Subsequently, messenger RNA was isolated from 10 5 to 10 6 unsorted and sorted cells. Oligo-dT purified mRNA was reverse transcribed using AMV reverse transcriptase (Amersham, Arlington Heights, IL, USA). Subsequently, 1 l of the first-strand cDNA template reaction was added to a standard PCR mix with oligonucleotide primers specific for the full-length cDNA of IL-1␤ (Clontech, Palo Alto, CA, USA). Actin specific primers were used as a control as previously described. 1 Fidelity of the amplified sequences was confirmed by fragment size comparison with a known control. 1 Reactions without DNA template were run with every experiment as a negative control (data not shown).
Results
Patient characteristics
Eleven patients with Waldenstrom's macroglobulinemia and two patients with IgM multiple myeloma were investigated by ISH (Table 1 ). All patients with WM had bone marrow biopsies consistent with the diagnosis, an IgM M-protein in the serum, and required chemotherapy. Seven of 11 patients with WM had an M-protein Ͼ3 g/dl and five patients had bone surveys performed and these were negative for osteolytic disease. Two patients were diagnosed with IgM MM because their bone surveys demonstrated significant osteolytic disease.
Contrast in IL-1␤ expression between patients with WM and IgM MM
In Figure 1a , ISH was performed on a bone marrow aspirate from a patient with an IgG kappa myeloma and demonstrated kappa and IL-1␤ reactivity, shown by the strong brown-black cytoplasmic staining. The myeloma cells were negative for lambda and all slides were counterstained in hematoxylin. In panel b, a bone marrow aspirate from a Waldenstrom's patient showed kappa mRNA expression but was negative for lambda, and IL-1␤ expression. In panel c, bone marrow cells from a patient with an IgM M-protein and lytic bone lesions showed detectable IL-1␤ mRNA expression by ISH.
ISH for kappa, lambda, and IL-1␤ expression was performed on bone marrow aspirates from each of the 13 patients ( Table 2) . None of the neoplastic cells from the 11 patients with WM showed detectable IL-1␤ expression by ISH. However, the neoplastic cells from both patients with IgM MM expressed IL-1␤ mRNA at high levels by ISH.
Correlation of ISH and RT/PCR for IL-1␤ expression
One of the patients with IgM MM had a concurrent marrow aspirate sorted by flow cytometry using anti-CD38 and anti-CD45 antibodies. After mRNA isolation, RT-PCR was performed with specific cytokine primers to detect the presence of IL-1␤ and actin. As shown in Figure 2 , IL-1␤ mRNA was 
Discussion
In this paper, we investigated IL-1␤ expression in IgM monoclonal gammopathy by in situ hybridization. Of the 13 patients that were examined, 11 were negative for IL-1␤ expression by ISH and these 11 had a clinical diagnosis of Waldenstrom's requiring chemotherapy. Five of the 11 patients had metastatic bone surveys performed and all five were negative for bone lesions. Two of the 13 patients were IL-1␤ positive by ISH and these two individuals were diagnosed with IgM multiple myeloma. Both patients exhibited osteolytic disease on bone survey and required chemotherapy. The results observed in patients with IgM MM parallel our previous work with myeloma of other isotypes (G, A, light chain only) in which IL-1␤ is abnormally upregulated in the plasma cells from Ͼ95% of myeloma patients.
2,3 Therefore, IL-1␤ expression is independent of the M-protein isotype and parallels the biology of the neoplastic clone. This presumes that the IL-1␤ mRNA is translated into IL-1␤ protein. Sati et al, 16 using an indirect immunofluorescence technique, were unable to detect IL-1␤ protein in the clonal plasma cells. However, using biological assays, several different investigators have shown that short-term cultures of purified mononuclear cells containing Ͼ90% plasma cells produce IL-1␤ at the protein level. 8, 9, 17 Waldenstrom's macroglobulinemia differs from MM in several clinical respects such as the presence of bone lesions in less than 10% of cases. The two patients with IgM MM both exhibited osteolytic disease on their radiographic bone surveys and the bone marrow plasma cells from both expressed IL-1␤ mRNA. Torcia et al 7 have shown a critical role for IL-1␤ in the pathogenesis of bone disease in myeloma by demonstrating that the OAF activity of myeloma cells from patients is almost completely related to IL-1␤. Since IL-1␤ has potent osteoclast activating factor activity, IL-1␤ production may account for the presence of lytic disease in the small percentage of patients with IgM monoclonal gammopathies exhibiting osteolytic disease.
The data presented here are supported by a comparison of serum IL-6 levels in MM and WM. Carter et al 9 have shown that the IL-1␤ produced by myeloma cells can induce IL-6 production by marrow stromal cells in a paracrine fashion. Furthermore, several investigators have documented high IL-6 levels in myeloma. [18] [19] [20] [21] If the IL-1␤ produced by the neoplastic B cells is responsible for the paracrine IL-6 production and elevated serum IL-6 levels, then one would predict that patients with MM will have higher serum IL-6 levels than those with WM. Indeed, the work by Du Villard et al 19 suggests that patients with MM have higher serum IL-6 levels, on average, when compared to individuals with WM or MGUS. However, our studies do not exclude the possibility that some patients with WM may express IL-1␤ or that, in a given patient with WM, the lymphoid component may express IL-1␤ differently from the plasma cell component. These differences in IL-1␤ production may result in various clinical manifestations among different patients.
In summary, IL-1␤ is not detectable in normal plasma cells but is aberrantly produced by plasma cells from virtually all patients with MM. This paper demonstrates that this observation now extends to patients with IgM MM, as well. IL-1␤ has potent osteoclast activating factor (OAF) activity, can induce the expression of several adhesion molecules such as ICAM-1 and VCAM-1 and stimulate IL-6, the central growth factor for myeloma cells. [4] [5] [6] [7] [8] [9] These biologic effects of IL-1␤ closely parallel several of the clinical features of human myeloma such as osteolytic bone lesions, IL-6-induced cell growth, and 'homing' of myeloma cells to the bone marrow suggesting that upregulation of IL-1␤ may be critical to the pathogenesis of myeloma.
3,10 Therefore, differences in IL-1␤ production between patients with MM and WM may explain some of the clinical differences between these two diseases, ie whether patients develop bone disease. This knowledge will be critical for the rational use of IL-1 inhibitors in the future in patients with various monoclonal gammopathies.
